Oropharyngeal or esophageal candidiasis :
ADULTS: PO/IV 200 mg first day, followed by 100 mg qd thereafter
for minimum of 2 wk for oropharyngeal candidiasis or 3 wk for esophageal
candidiasis. CHILDREN: PO/IV 6 mg/kg on first day, followed by 3 mg/kg qd
thereafter for minimum of 2 wk for oropharyngeal candidiasis or 3 wk (at least 2
weeks after symptom resolution) for esophageal candidiasis.
Vaginal candidiasis :
ADULTS: PO 150 mg single dose.
Prevention of candidiasis in bone marrow transplant :
ADULTS: PO/IV 400 mg once daily; in patients with anticipated
severe granulocytopenia (< 500 neutrophils/mm3) start fluconazole several days
before anticipated onset and continue 7 days after neutrophil count rises > 1000
cells/mm3.
Cryptococcal meningitis :
ADULTS: PO/IV 400 mg first day, followed by 200 mg qd thereafter
(400 mg may be used) for 10 to 12 wk after CSF culture is negative for initial
meningitis; 200 mg qd for suppression of relapse of cryptococcal meningitis.
Candidemia and disseminated candida infections :
CHILDREN: PO/IV 6 to 12 mg/kg/day.
Cryptococcal meningitis 12 mg/kg on first day, followed by 6
mg/kg/day (or 12 mg/kg/day based on medical judgment of patient's response).
Recommended duration is 10 to 12 weeks after CSF becomes culture negative.
Suppression of relapse in AIDS patients 6 mg/kg/day. NEONATES:
Experience is limited to pharmacokinetic studies in premature newborns.
Prolonged half-life has been noted. These children, in the first 2 wk of life,
should receive the same mg/kg dosage as other children, but administered every
72 hr. After the first 2 wk, dose once daily.
